ARS Pharmaceuticals Inc计划于夏季前向加拿大监管机构提交其Neffy 1毫克产品的审批申请,该产品适用于体重在15至30公斤之间的儿童群体。
ARS Pharmaceuticals Inc计划于夏季前向加拿大监管机构提交其Neffy 1毫克产品的审批申请,该产品适用于体重在15至30公斤之间的儿童群体。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.